A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Summary

This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma. The drugs involved in this study are: * Durvalumab * Tremelimumab

Timeline

Start

2017-04-10

Primary completion

2019-06-07

Completion

2024-12-16

Outcome

Outcome not reported

Stopped: “Criteria not met for second stage at time of interim analysis”

Drugs

Indications